Hepatitis a vaccine - Biologic Drug Details

Summary for hepatitis a vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for hepatitis a vaccine

Recent Clinical Trials for hepatitis a vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assiut University	Early Phase 1
Erasmus Medical Center	Phase 1/Phase 2
ISA Pharmaceuticals B.V.	Phase 1/Phase 2

See all hepatitis a vaccine clinical trials

Pharmacology for hepatitis a vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis A Virus Vaccine
Chemical Structure	Hepatitis A Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hepatitis a vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hepatitis a vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for hepatitis a vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Hepatitis A Vaccine

Market Overview

The Hepatitis A vaccine market is a significant segment within the broader vaccines industry, driven by increasing outbreaks of hepatitis A, rising awareness about immunization, and favorable government policies. Here are the key dynamics and financial projections for this market.

Market Size and Growth

• The Hepatitis A vaccine market was valued at USD 876.9 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 3.5% from 2022 to 2029[1].
• Another estimate suggests the market was valued at USD 742.31 million in 2023 and is projected to reach USD 948.16 million by 2034, with a CAGR of 2.25% from 2024 to 2034[4].

Market Segmentation

By Type

• Inactivated Vaccines: This segment dominated the market in 2023 and is expected to continue its dominance. Inactivated vaccines are safe, highly functional, and cannot convert into virulent forms, making them widely preferred[1][4].
• Live Attenuated Vaccines: Although less dominant, live attenuated vaccines are expected to grow rapidly. These vaccines produce a robust immune response and are particularly favored in regions like China[1][4].

By Application

• Government Institutions: Government institutions lead the market by providing vaccines at affordable costs through various immunization programs and awareness campaigns[1][4].

Geographical Penetration

• Asia-Pacific: This region dominates the Hepatitis A vaccine market, driven by high epidemiology of hepatitis A, favorable government policies, and increasing investments in India and China. China is notable for developing, manufacturing, and distributing live attenuated hepatitis A vaccines[1][4].
• Europe: Europe is also expected to show significant growth due to the easy availability of vaccines at lower costs[1].
• North America: This region is anticipated to grow rapidly, driven by the presence of key players, advanced manufacturing infrastructure, and favorable government policies. The Canadian government, for example, provides free hepatitis A vaccines to high-risk groups[4].

Competitive Landscape

The Hepatitis A vaccine market is highly competitive, with major players such as GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, and Zhejiang Pukang. These companies are adopting new expansion strategies to drive global growth[1].

Drivers and Opportunities

Increasing Outbreaks and Awareness

• The rise in hepatitis A outbreaks and increasing awareness about immunization are key drivers. According to the WHO, around 354 million people globally suffer from hepatitis A, leading to a higher demand for vaccines[4].

Government Policies and Programs

• Favorable government policies and immunization programs significantly boost the market. For instance, the Indian Government’s “Make in India” policy promotes indigenous manufacturing of hepatitis A vaccines[4].

Technological Advancements

• Advances in vaccine technologies, such as the development of live attenuated vaccines, are expected to enhance market growth[3].

Challenges

Lack of Awareness

• A significant challenge is the lack of awareness about hepatitis A among individuals, which can curtail market growth. Resistance to diagnosis also hampers market expansion[1].

COVID-19 Impact

• The COVID-19 pandemic had a negative impact on the global Hepatitis A vaccine market, although the market is recovering as vaccination programs resume[1].

Financial Trajectory

Revenue Projections

• The global Hepatitis A vaccine market is projected to grow from USD 742.31 million in 2023 to USD 948.16 million by 2034, indicating a steady increase in revenue[4].

Cost-Effectiveness

• Catch-up vaccination programs are considered cost-effective. For example, a cost analysis by the CDC suggests that incremental costs of catch-up hepatitis A vaccination are reasonable and efficient, especially given the higher coverage rates among vaccinated children[2].

Investment and Collaboration

• Increasing investments and collaborations in the Asia-Pacific region, particularly in India and China, are expected to drive market growth. Government initiatives and public-private partnerships play a crucial role in this expansion[4].

Key Statistics

• Market Size: USD 876.9 million in 2021, projected to grow at a CAGR of 3.5% from 2022 to 2029[1].
• Global Demand: Around 37 million doses globally, with 13 million doses utilized by 16 countries in the Americas[4].
• Epidemiology: Approximately 354 million people globally suffer from hepatitis A, with 1.3 million deaths annually[4].

Quotes from Industry Experts

"The increasing outbreaks of hepatitis A and rising incidences of HIV and chronic liver disease increase the need for hepatitis A vaccines. Favorable government policies and WHO guidelines for immunization boost the market."[4]

Illustrative Statistics

• Asia-Pacific Dominance: This region accounts for the highest demand for hepatitis A vaccines, with China representing 22% of the global demand[4].
• Cost-Effectiveness: Catch-up vaccination programs can save lives at a relatively low cost. For instance, Ohio’s “Vax-a-Million” lottery increased vaccinations at an estimated cost of $75 per additional dose[5].

Highlight

"The global vaccines market, including COVID-19 vaccines, is estimated to grow from USD 78.0 billion in 2024 to USD 94.9 billion by 2029, at a CAGR of 4.0%."[3]

Key Takeaways

• The Hepatitis A vaccine market is driven by increasing outbreaks, rising awareness, and favorable government policies.
• Inactivated vaccines dominate the market, but live attenuated vaccines are growing rapidly.
• Asia-Pacific, particularly China and India, are key regions driving market growth.
• Major players are adopting new strategies to expand their global presence.
• Despite challenges like lack of awareness and COVID-19 impacts, the market is expected to grow steadily.

FAQs

What is the current market size of the Hepatitis A vaccine market?

The Hepatitis A vaccine market was valued at USD 876.9 million in 2021 and USD 742.31 million in 2023[1][4].

What is the projected growth rate of the Hepatitis A vaccine market?

The market is expected to grow at a CAGR of 3.5% from 2022 to 2029 and 2.25% from 2024 to 2034[1][4].

Which region dominates the Hepatitis A vaccine market?

Asia-Pacific, particularly China and India, dominate the market due to high epidemiology and favorable government policies[1][4].

What are the main types of Hepatitis A vaccines?

The main types are inactivated vaccines and live attenuated vaccines, with inactivated vaccines being the dominant segment[1][4].

How do government policies impact the Hepatitis A vaccine market?

Government policies and immunization programs significantly boost the market by providing vaccines at affordable costs and promoting awareness[1][4].

What is the impact of COVID-19 on the Hepatitis A vaccine market?

The COVID-19 pandemic had a negative impact, but the market is recovering as vaccination programs resume[1].

Sources

1. Global Hepatitis A Vaccine Market - 2022-2029 - MarketResearch.com
2. Evidence to Recommendations for Use of Hepatitis A Vaccine Catch-up - CDC
3. Vaccines Market Growth, Drivers, and Opportunities - MarketsandMarkets
4. Hepatitis A Vaccine Market Size, Demand and Trends by 2034 - Towards Healthcare
5. The Ohio Vaccine Lottery and Starting Vaccination Rates - Oberlin College

Last updated: 2024-12-20